Neurocrine Biosciencesvs.Regeneron
NBIX vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 5.3× larger than Neurocrine Biosciences by market cap; Regeneron trades at the lower P/E (19.0 vs 22.0).
Side by side
| NBIX | REGN | |
|---|---|---|
| Market cap | $15.5B | $82.2B |
| Price | $153.37 | $833.56 |
| Today | +0.2% | +0.6% |
| Return YTD | +7.9% | +7.3% |
| Return 1Y | +13.0% | +40.5% |
| P/E | 22.0 | 19.0 |
| P/S | 4.6 | 5.3 |
| P/B | 4.2 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More NBIX & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where NBIX and REGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →